Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS) (SLIPS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03371862|
Recruitment Status : Not yet recruiting
First Posted : December 13, 2017
Last Update Posted : July 1, 2019
|Condition or disease||Intervention/treatment||Phase|
|Short Bowel Syndrome||Drug: Liraglutide Pen Injector [Victoza]||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Pilot study|
|Masking:||None (Open Label)|
|Official Title:||Pilot Study of the GLP-1 Agonist, Liraglutide, on Decreasing Parenteral Support Requirements in Short Bowel Patients.|
|Estimated Study Start Date :||October 28, 2019|
|Estimated Primary Completion Date :||August 30, 2020|
|Estimated Study Completion Date :||September 30, 2020|
|Experimental: Test group||
Drug: Liraglutide Pen Injector [Victoza]
Pilot study of liraglutide in patients with short bowel.
- Improvement in parenteral support [ Time Frame: 20 weeks post start of drug ]Improvement of parenteral support on 20 weeks of Liraglutide
- Improvement in quality of life [ Time Frame: 20 weeks post start of drug ]Improvement in Euroqol EQ5-D score. Level 1: indicating no problem, Level 5: indicating extreme problems.
- Duration of response [ Time Frame: 20 weeks ]Duration of response i.e. proportion of subjects who maintain reduction in weekly PN volume from baseline at week 20.
- Days/Nights not requiring PS [ Time Frame: 20 weeks ]Days/Nights not requiring PS
- Change in plasma citrulline, GLP-1, IGF-1 and PYY concentrations [ Time Frame: 20 weeks ]Change in plasma citrulline, GLP-1, IGF-1 and PYY concentrations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03371862
|Contact: Siddhartha Oke, MBBS||0208 235 firstname.lastname@example.org|
|St Mark's Hospital||Recruiting|
|Harrow, United Kingdom, HA1 3UJ|
|Contact: Siddhartha Oke, MBBS 02082354196 email@example.com|
|Principal Investigator:||Siddhartha Oke||Imperial College London|